+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.

Age: 14Years +All GendersPhase 3
42 locations
C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.

Age: 18Years +All GendersPhase 3
259 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations
P

Actively Recruiting

Researchers are evaluating the investigational drug PF-06821497 mevrometostat combined with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer mCRPC who have not previously received certain systemic treatments. This global, multicenter, randomized Phase 3 study focuses on participants who have mCRPC but have only received androgen deprivation therapy or first-generation anti-androgen agents, excluding prior treatment with androgen receptor signaling inhibitors such as enzalutamide or abiraterone. Participants are randomly assigned to one of two groups one receiving PF-06821497 twice daily plus enzalutamide once daily, and the other receiving a placebo twice daily plus enzalutamide once daily. The study includes several phases screening, randomization, treatment, safety follow-up, and long-term follow-up. Treatment is continuous oral dosing during the treatment phase. Throughout the study, participants will undergo regular assessments including scans, laboratory tests, and patient-reported questionnaires to measure outcomes such as radiographic progression-free survival, overall survival, pain progression, prostate specific antigen levels, and quality of life. Safety is monitored continuously, and follow-up can last up to approximately five years after randomization to evaluate long-term effects and treatment impact.

Age: 18Years +MALEPhase 3
231 locations
B

Actively Recruiting

Researchers are evaluating nurse-led treatment for rifampicin-resistant tuberculosis RR-TB in primary care clinics compared to standard physician-led treatment at district hospitals in South Africa. This multi-site, cluster randomized trial aims to assess treatment outcomes, safety, and patient costs over five years. The study also explores how this approach affects HIV co-infected patients and addresses the high costs and access barriers associated with hospital-based care. Participants will receive RR-TB treatment either through nurses available once or twice weekly at primary care clinics or through physicians at hospital outpatient sites. Nurse availability will rotate between clinics to mirror physician duties. The trial will compare the two approaches for treatment success, safety events, and catastrophic costs exceeding 20% of household income. Secondary goals include evaluating timing for treatment initiation, symptom resolution, provider adherence, and cost-effectiveness. During the study, participants will be closely monitored through laboratory tests, clinical assessments, and cost tracking over 12 months. Key outcomes include treatment success at six months, severe adverse events within a year, and patient cost burdens. The study involves regular evaluations of dosing adjustments and HIV-related treatment milestones. Participation spans from initial diagnosis through a year of follow-up, with blinded analysis and safety reviews to ensure data integrity.

Age: 18Years +All GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are conducting a phase III randomized controlled trial called INTENSE-TBM to evaluate treatments aimed at reducing death rates in adolescents and adults with tuberculous meningitis, including those with or without HIV infection in sub-Saharan Africa. The trial compares intensified tuberculosis meningitis treatment using high-dose rifampicin and linezolid against the World Health Organizations standard treatment, and also examines the effects of aspirin compared to a placebo. This study is carried out across multiple countries including Cte dIvoire, Madagascar, Uganda, and South Africa. Participants are randomly assigned to one of four groups standard WHO tuberculosis meningitis treatment with aspirin placebo, standard treatment with aspirin, intensified treatment with aspirin placebo, or intensified treatment with aspirin. The intensified treatment includes high doses of rifampicin and linezolid for the first eight weeks, followed by standard doses of rifampicin and isoniazid until week 40. Aspirin or placebo is taken daily during the first eight weeks. After week 8, all participants continue with standard treatment until week 40. During the 40-week follow-up, participants undergo regular assessments to monitor survival, neurological events, adverse effects, and disability. Laboratory tests, including culture and drug resistance evaluations, as well as pharmacokinetic studies in subsets of patients, are conducted. HIV-infected participants will have additional monitoring of AIDS-related illnesses, viral load, and immune cell counts. The primary outcome measures the rate of death from any cause up to 40 weeks, with secondary outcomes assessing safety, effectiveness, and quality of life related factors.

Age: 15Years +All GendersPhase 3
13 locations
N

Actively Recruiting

Healthy Volunteer

Researchers are conducting a nationwide study in South Africa to develop the first nationally representative blood pressure and anthropometric reference values for children aged 5 to under 18 years. This study addresses the lack of appropriate African ancestry data, which currently results in reliance on European and US standards that may not suit the South African paediatric population. The goal is to improve understanding of blood pressure and hypertension in children and to establish clinical guidelines tailored to this population. The study involves measuring blood pressure and body measurements in a randomized sample of approximately 22,464 school-aged children from all provinces and various urban, peri-urban, and rural settings. Data collection will take place over five years, capturing a diverse group representative of South Africas ethnic and socioeconomic backgrounds. These measurements will be used to create nomograms and inform national guidelines for hypertension management in children. Participants will have their blood pressure and anthropometric data collected during the study period. Researchers will analyze these data to determine normal reference values and develop clinical practice guidelines for managing childhood hypertension. The information gathered will also support community engagement and awareness initiatives. The studys findings aim to guide healthcare providers and inform national health policies for better paediatric hypertension care in South Africa.

Age: 5Years - 18YearsAll Genders
11 locations

1-10 of 16

1